Literature DB >> 32468476

Amyotrophic Lateral Sclerosis: Current Status in Diagnostic Biomarkers.

Katerina Kadena1, Panayiotis Vlamos2.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a rare, neurodegenerative disease that affects the human motor system. ALS is a highly heterogeneous disease, depending on several causative factors. The heterogeneity of the disease is also reflected in the variation of the symptoms in ALS patients. The worldwide annual incidence of ALS is about 2.08 per 100,000 with uniform rates in Caucasian populations and lower rates in African, Asian, and Hispanic populations, while the number of individuals with ALS is expected to grow significantly between 2015 and 2040 with an estimated increase of 69% (Chio et al. 2013a; Arthur et al. 2016).

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32468476     DOI: 10.1007/978-3-030-32633-3_26

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  52 in total

1.  Biomarkers in amyotrophic lateral sclerosis: combining metabolomic and clinical parameters to define disease progression.

Authors:  H Blasco; L Nadal-Desbarats; P-F Pradat; P H Gordon; B Madji Hounoum; F Patin; C Veyrat-Durebex; S Mavel; S Beltran; P Emond; C R Andres; P Corcia
Journal:  Eur J Neurol       Date:  2015-10-28       Impact factor: 6.089

Review 2.  Further development of biomarkers in amyotrophic lateral sclerosis.

Authors:  H Blasco; P Vourc'h; P F Pradat; P H Gordon; C R Andres; P Corcia
Journal:  Expert Rev Mol Diagn       Date:  2016-06-20       Impact factor: 5.225

3.  Axonal damage markers in cerebrospinal fluid are increased in ALS.

Authors:  J Brettschneider; A Petzold; S D Süssmuth; A C Ludolph; H Tumani
Journal:  Neurology       Date:  2006-03-28       Impact factor: 9.910

Review 4.  Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis.

Authors:  Peggy Barschke; Patrick Oeckl; Petra Steinacker; Albert Ludolph; Markus Otto
Journal:  Expert Rev Proteomics       Date:  2017-08-14       Impact factor: 3.940

Review 5.  ALS biomarkers for therapy development: State of the field and future directions.

Authors:  Michael Benatar; Kevin Boylan; Andreas Jeromin; Seward B Rutkove; James Berry; Nazem Atassi; Lucie Bruijn
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

Review 6.  Metabolomics in amyotrophic lateral sclerosis: how far can it take us?

Authors:  H Blasco; F Patin; B Madji Hounoum; P H Gordon; P Vourc'h; C R Andres; P Corcia
Journal:  Eur J Neurol       Date:  2016-01-29       Impact factor: 6.089

7.  Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis.

Authors:  Han-Jou Chen; Georgia Anagnostou; Andrea Chai; James Withers; Alex Morris; Jason Adhikaree; Giuseppa Pennetta; Jackie S de Belleroche
Journal:  J Biol Chem       Date:  2010-10-12       Impact factor: 5.157

Review 8.  New developments and future opportunities in biomarkers for amyotrophic lateral sclerosis.

Authors:  Xueping Chen; Hui-Fang Shang
Journal:  Transl Neurodegener       Date:  2015-09-30       Impact factor: 8.014

9.  Altered microRNA expression profile in Amyotrophic Lateral Sclerosis: a role in the regulation of NFL mRNA levels.

Authors:  Danae Campos-Melo; Cristian A Droppelmann; Zhongping He; Kathryn Volkening; Michael J Strong
Journal:  Mol Brain       Date:  2013-05-24       Impact factor: 4.041

10.  Projected increase in amyotrophic lateral sclerosis from 2015 to 2040.

Authors:  Karissa C Arthur; Andrea Calvo; T Ryan Price; Joshua T Geiger; Adriano Chiò; Bryan J Traynor
Journal:  Nat Commun       Date:  2016-08-11       Impact factor: 14.919

View more
  1 in total

1.  Tear-Based Vibrational Spectroscopy Applied to Amyotrophic Lateral Sclerosis.

Authors:  Diletta Ami; Alessandro Duse; Paolo Mereghetti; Federica Cozza; Francesca Ambrosio; Erika Ponzini; Rita Grandori; Christian Lunetta; Silvia Tavazzi; Fabio Pezzoli; Antonino Natalello
Journal:  Anal Chem       Date:  2021-12-14       Impact factor: 6.986

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.